[go: up one dir, main page]

WO2004037199A3 - Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation - Google Patents

Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2004037199A3
WO2004037199A3 PCT/US2003/033757 US0333757W WO2004037199A3 WO 2004037199 A3 WO2004037199 A3 WO 2004037199A3 US 0333757 W US0333757 W US 0333757W WO 2004037199 A3 WO2004037199 A3 WO 2004037199A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pain
compositions
management
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/033757
Other languages
English (en)
Other versions
WO2004037199A2 (fr
Inventor
Jerome B Zeldis
Herbert Faleck
Donald C Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to AU2003286663A priority Critical patent/AU2003286663B2/en
Priority to JP2004547126A priority patent/JP2006507284A/ja
Priority to CA002503536A priority patent/CA2503536A1/fr
Priority to BR0315609-5A priority patent/BR0315609A/pt
Priority to EP03777871A priority patent/EP1556044A2/fr
Priority to MXPA05004182A priority patent/MXPA05004182A/es
Priority to NZ540028A priority patent/NZ540028A/en
Priority to HK06108551.8A priority patent/HK1088225B/xx
Publication of WO2004037199A2 publication Critical patent/WO2004037199A2/fr
Publication of WO2004037199A3 publication Critical patent/WO2004037199A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes permettant de traiter, de prévenir, de modifier et de soulager divers types de douleur. Des méthodes spécifiques consistent, d'une part, à administrer un composé immunomodulateur ou un sel, solvate, hydrate, stéréo-isomère, clathrate ou promédicament pharmaceutiquement acceptable de ce composé, seul ou combiné avec un second agent actif, et/ou, d'autre part, à conduire une thérapie chirurgicale, psychologique ou physique. L'invention concerne également des compositions pharmaceutiques, des formes posologiques monodoses et des trousses convenant pour une utilisation dans les méthodes selon l'invention.
PCT/US2003/033757 2002-10-24 2003-10-24 Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation Ceased WO2004037199A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2003286663A AU2003286663B2 (en) 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2004547126A JP2006507284A (ja) 2002-10-24 2003-10-24 疼痛を治療、改変および管理するための免疫調節化合物の使用方法および組成物
CA002503536A CA2503536A1 (fr) 2002-10-24 2003-10-24 Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation
BR0315609-5A BR0315609A (pt) 2002-10-24 2003-10-24 Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
EP03777871A EP1556044A2 (fr) 2002-10-24 2003-10-24 Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation
MXPA05004182A MXPA05004182A (es) 2002-10-24 2003-10-24 Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento, modificacion y manejo del dolor.
NZ540028A NZ540028A (en) 2002-10-24 2003-10-24 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
HK06108551.8A HK1088225B (en) 2002-10-24 2003-10-24 Compositions comprising immunomodulatory compounds for treatment, modification and management of pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42100302P 2002-10-24 2002-10-24
US60/421,003 2002-10-24

Publications (2)

Publication Number Publication Date
WO2004037199A2 WO2004037199A2 (fr) 2004-05-06
WO2004037199A3 true WO2004037199A3 (fr) 2004-12-23

Family

ID=32176661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033757 Ceased WO2004037199A2 (fr) 2002-10-24 2003-10-24 Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation

Country Status (12)

Country Link
EP (1) EP1556044A2 (fr)
JP (1) JP2006507284A (fr)
KR (1) KR20050057672A (fr)
CN (2) CN101108185A (fr)
AU (1) AU2003286663B2 (fr)
BR (1) BR0315609A (fr)
CA (1) CA2503536A1 (fr)
MX (1) MXPA05004182A (fr)
NZ (1) NZ540028A (fr)
TW (1) TW200503683A (fr)
WO (1) WO2004037199A2 (fr)
ZA (1) ZA200503240B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
JP2008534630A (ja) * 2005-04-08 2008-08-28 ニューロメッド ファーマシューティカルズ リミテッド 疼痛の軽減のためのｎ型カルシウムチャネルブロッカーを含む組み合わせ治療の方法
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
JP4382735B2 (ja) * 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
CN101495111A (zh) * 2006-05-26 2009-07-29 细胞基因公司 在联合治疗中使用免疫调节化合物的方法和组合物
CN101557806A (zh) * 2006-10-19 2009-10-14 细胞基因公司 使用免疫调节化合物治疗和控制螺旋体和其它专性胞内菌疾病的方法和组合物
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6395754B1 (en) * 1997-05-30 2002-05-28 Celgene Corporation, Et Al. Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNFα levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT925294E (pt) * 1996-07-24 2003-04-30 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
SE0101256D0 (sv) * 2001-04-06 2001-04-06 A & Science Invest Ab Treatment of low back pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
US6395754B1 (en) * 1997-05-30 2002-05-28 Celgene Corporation, Et Al. Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels

Also Published As

Publication number Publication date
CN101108185A (zh) 2008-01-23
CN1326522C (zh) 2007-07-18
EP1556044A2 (fr) 2005-07-27
AU2003286663A1 (en) 2004-05-13
TW200503683A (en) 2005-02-01
CA2503536A1 (fr) 2004-05-06
BR0315609A (pt) 2005-08-23
HK1088225A1 (en) 2006-11-03
JP2006507284A (ja) 2006-03-02
MXPA05004182A (es) 2005-06-08
NZ540028A (en) 2009-07-31
ZA200503240B (en) 2007-11-28
KR20050057672A (ko) 2005-06-16
CN1732000A (zh) 2006-02-08
WO2004037199A2 (fr) 2004-05-06
AU2003286663B2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2005044178A3 (fr) Procedes d'utilisation et compositions comprenant des composes immunomodulaires pour traiter, modifier et gerer la douleur
WO2005046318A3 (fr) Procedes d'utilisation et compositions comprenant des composes immunomodulatoires pour le traitement et la gestion de maladies et de troubles associe(e)s a l'amiante
EP1487461A4 (fr) Procedes d'utilisation de composes immunomodulateurs pour le traitement et la gestion des syndromes myelodysplastiques et compositions contenant ces composes
EP2210606A3 (fr) Compositions Recourant à des Composés Immunomodulatoires pour le Traitement et la Gestion de Syndromes Myéloprolifératifs
WO2005105088A3 (fr) Procedes d'utilisation et compositions comportant des composes immunomodulateurs pour le traitement et le controle de l'hypertension pulmonaire
WO2004037207A3 (fr) Compositions contenant des medicaments selectifs inhibiteurs des cytokines, destinees a traiter, modifier et gerer la douleur, et leurs methodes d'utilisation
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
WO2004039325A3 (fr) Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation
WO2007126964A3 (fr) Inhibiteurs de kinase
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
IL178591A (en) 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes
WO2004034962A3 (fr) Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplasiques
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques
WO2004037199A3 (fr) Compositions contenant des composes immunomodulateurs pour le traitement, la modification et le soulagement de la douleur et leurs methodes d'utilisation
WO2004041190A3 (fr) Compositions comprenant des composes immunomodulateurs pour le traitement et la gestion d'une degeneration maculaire, ainsi que leurs methodes d'utilisation
WO2005039497A3 (fr) Procedes et compositions a base de thalidomide pour le traitement des fibromyalgies
WO2004041191A3 (fr) Methodes de traitement, de prevention et de gestion de la degenerescence maculaire
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
WO2001045715A3 (fr) Formulations d'agonistes d'adenosine a1
WO2005046594A3 (fr) Methodes d'utilisation et compositions comprenant un inhibiteur de jnk pour le traitement et pour la gestion de maladies et de troubles associes a l'amiante
WO2004041181A3 (fr) Methodes d'utilisation et compositions contenant des substances medicamenteuses d'inhibition selective des cytokines pour traiter et controler la degenerescence
WO2004029025A3 (fr) Methodes et compositions pour traiter des troubles auto-immunes a l'aide de clofarabine
WO2005065372A3 (fr) Procedes et compositions faisant intervenir de la thalidomide pour le traitement et la prise en charge de troubles et maladies du systeme nerveux central
WO2004043336A3 (fr) Methodes d'utilisation d'agents inhibiteurs selectifs de la cytokine et compositions comprenant ces agents pour le traitement et la gestion de maladies myeloproliferatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004182

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 168206

Country of ref document: IL

Ref document number: 2005/03240

Country of ref document: ZA

Ref document number: 200503240

Country of ref document: ZA

Ref document number: 2004547126

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2503536

Country of ref document: CA

Ref document number: 1020057007000

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003286663

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003777871

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 540028

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020057007000

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038A75310

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003777871

Country of ref document: EP